CNS Pharmaceuticals, Inc.
$0.14
0.03 (29.87%)
CNSP Price Chart
| Basic | |
|---|---|
| Market Cap | $8.05M |
| Price | $0.14 |
| 52 Week Range | 0.084-23.9 |
| Beta | 1.02 |
| Margins | |
| Gross Profit Margin | 60.34% |
| Operating Profit Margin | -268488.86% |
| Net Profit Margin | -268102.56% |
| Valuation (TTM) | |
| P/E Ratio | -4.06 |
| Price to Sales Ratio | 1343.73 |
| Price to Book Ratio | 20.64 |
| PEG Ratio | -0.19 |
Industry
Biotechnology
Sector
Healthcare
Full-Time Employees
3
Website
IPO Date
2019-11-08T00:00:00.000Z
Description
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Phone
800 946 9185
Address
2100 West Loop South, Houston, TX, 77027, US
CIK
0001729427